Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Labrys Biologics

Finance Watch: Two New VC Funds Target Early Stage And Beyond

Private Company Edition: venBio’s new fund plus Ysios Capital’s recent €216m ($260m) fund adds up to $810m in fresh venture capital for life science companies. Also, Nikang and Esco attracted $200m each in VC investment, Pulmocide closed a $92m series C round and Stablix launched with $63m. 

Financing Innovation

Migraine Medicine Competition: Teva Seeks To Halt Launch Of Emgality

Under emerging pricing strategy, Lilly will provide Emgality free for up to 12 months to commercially insured patients; Amgen has similar program for Aimovig.

Pricing Strategies Intellectual Property

Teva's CGRP Inhibitor Fails In Chronic Cluster Headaches, Continues In Episodic

Unlike the migraine space, there is only one competitor for Teva's CGRP inhibitor in cluster headaches, but that opportunity narrowed with fremanezumab's failure in chronic cluster headaches, though a trial in episodic cluster headaches is ongoing.

Neurology Clinical Trials

Pionyr Maps Tumor Microenvironment, Plans 'Surgical' Strikes

Emerging Company Profile: Pionyr Immunotherapeutics exec who once led early development for Merck's PD-1 inhibitor Keytruda explains the San Francisco start-up's approach to rebalancing the tumor's microenvironment in order to improve outcomes.

StartUps and SMEs ImmunoOncology
See All

Company Information

UsernamePublicRestriction

Register